Biotech Profile
Ciloa – First to Overcome 30-Year Challenge of Stable, Functional Recombinant Adiponectin Production
French biotech Ciloa outlines how 14 years of exosome engineering trials led to breakthrough adiponectin biotherapeutic now advancing toward Phase I trials in 2027. CEO Robert Z. Mamoun describes the transition from retrovirus research to developing what the company claims
6 August 2025